title: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value.
authors.affiliation: Division of General Internal Medicine, Department of Medicine, University of California, San Francisco.
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Tice
authors.affiliation: Division of Cardiology, Department of Medicine, University of California San Francisco3Department of Epidemiology and Biostatistics, University of California, San Francisco4Center for Healthcare Value, University of California, San Francisco.
authors.forename: Dhruv S
authors.initials: DS
authors.lastname: Kazi
authors.affiliation: Institute for Clinical and Economic Review, Boston, Massachusetts.
authors.forename: Steven D
authors.initials: SD
authors.lastname: Pearson
mesh_terms: D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000924:Anticholesteremic Agents / Q000191:economics / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000097:blood / Q000188:drug therapy* / Q000191:economics; D008078:Cholesterol, LDL / Q000097:blood; D003362:Cost-Benefit Analysis; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy* / Q000191:economics; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases / Q000037:antagonists & inhibitors*; D012697:Serine Endopeptidases; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases; D012697:Serine Endopeptidases; C577155:evolocumab; C571059:alirocumab